Antibody Discovery & Development Strategies
11th October 2012 — 12th October 2012
Implementing New Antibody Methodologies to Strengthen the Target Selection Process and Improve Function and Efficiency
Key Conference Speakers:
Principal Scientist, Merrimack Pharmaceuticals
David Meininger, Ph.D., M.B.A.
Senior Director, Biologics Discovery, Merck & Co., Inc.
Mitchell Ho, Ph.D.
Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
Andrew E. Nixon, Ph.D
Vice President, Lead Discovery & Biochemistry, Discovery Research , Dyax Corp.
Delegates will attend this program to learn about the latest advancements in antibody discovery and development, including cutting-edge research on how to identify the correct target for an antibody, and how to streamline the entire development process to get more products out and reduce budget needs.
Attendees will also hear about hot topics such as bispecifics and the latest advancements in antibody drug conjugates (ADCs) and their impact on certain critical therapeutic areas. Key to the conference will be addressing a need for quality antibodies and learning about what leading companies such as Genentech, Bayer, Intrexon and Merck are producing in the way of new antibody treatments.
Follow us on Social Media:
Event Hashtag: #antibody2012
Vice Presidents, Directors, Chief Scientific Officers, Senior Scientists from the pharmaceutical and biotechnology industries: Antibody discovery, Antibody development, Monoclonal antibodies, Protein development
Expected Number of Attendees
View Conference Website: Antibody Discovery & Development Strategies
Price of Attendance
Email firstname.lastname@example.org for details.